MONMOUTH JUNCTION, N.J., March 5, 2019 /PRNewswire/ —¬†CytoSorbents Corporation¬†(NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb¬ģ¬†blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,¬†announced that it has expanded direct sales of CytoSorb for all applications to Poland and the Netherlands, and for critical care applications in Sweden, Denmark, and Norway.¬† As part of this effort, the company established CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH.

CytoSorbents Logo. (PRNewsFoto/CytoSorbents)

Dr. Christian Steiner, Senior Vice President of Sales and Marketing of CytoSorbents stated, “We are excited to expand into these territories, increasing the total number of direct countries to ten, where we will benefit from higher gross margin direct sales.¬† Last year, direct sales from Germany, Austria, Switzerland, Belgium and Luxembourg accounted for more than 70% of our total product revenue. Our new sales teams in each of these countries will leverage the existing product registrations and approvals of CytoSorb, our collective expertise on selling the product direct, and the ongoing efforts of Fresenius Medical Care (FMC) as our co-marketing partner in each of these territories, to rapidly gain sales this year. ¬†In addition to its co-marketing efforts, FMC will focus on its successes in critical care in France and Finland, while assuming exclusive distributorship in the Czech Republic for all applications, and pursuing significantly larger commercial opportunities in critical care in both Mexico and Korea.”

Poland, the Netherlands, Sweden, Denmark, and Norway have a collective population of 76 million people, with high standards of medical care and advanced medical practices.  As with most modernized countries, these territories struggle with the high burden of an aging population that is a major risk factor for life-threatening inflammatory illnesses and heart disease, creating a very favorable market for CytoSorb.

About CytoSorbents Corporation (NASDAQ: CTSO)

CytoSorbents Corporation¬†is a leader in critical care immunotherapy, specializing in blood purification.¬† Its flagship product,¬†CytoSorb¬ģ¬†is approved in the European Union with distribution ¬†in 55 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses.¬† These are conditions where the risk of death is extremely high, yet no effective treatments exist.¬†¬†CytoSorb¬ģ¬†is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. ¬†CytoSorbents is conducting its pivotal REFRESH 2-AKI trial ‚Äď a multi-center, randomized controlled, clinical trial intended to support U.S. regulatory approval of CytoSorb for use in a heart-lung machine during complex cardiac surgery to reduce organ injury.¬† CytoSorb¬ģ has been used in more than 56,000 human treatments to date.

CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of nearly¬†$26 million¬†from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (USSOCOM), and others. The Company has numerous products under development based upon this unique patented blood purification technology including CytoSorb-XL™, HemoDefend™, VetResQ™, K+ontrol™, ContrastSorb, DrugSorb, and others.¬†¬†For more information, please visit the Company’s websites¬†at¬†and¬†or follow us on¬†Facebook¬†and¬†Twitter.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on¬†March 8, 2018, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.

Please Click to Follow Us on Facebook and Twitter

Cytosorbents Contact:
Amy Vogel

Investor Relations

(732) 398-5394

[email protected]

Investor Relations Contact:

Jeremy Feffer

LifeSci Advisors


[email protected]¬†

Public Relations Contact:

Joshua Berkman

Rubenstein Public Relations


[email protected]


SOURCE CytoSorbents Corporation